Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
Clinical trial NCT02829840 · WITHDRAWN
Trial details
- NCT number
- NCT02829840
- Sponsor
- M.D. Anderson Cancer Center
- Status
- WITHDRAWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-01
- Primary completion
- 2021-09-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.